Quick Answer
Kyverna Therapeutics, Inc. reported Net Income Loss of -$161.31 million for the year ending 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -26.5% in Net Income Loss from 2024 to 2025.
- This data is from Kyverna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$11.14 million | Q2 2023: -$13.09 million | Q3 2023: -$15.47 million | Q1 2024: -$26.69 million | Q2 2024: -$28.80 million | Q3 2024: -$34.49 million | Q1 2025: -$44.64 million | Q2 2025: -$42.08 million | Q3 2025: -$36.79 million.
- Over the full 3 years of available data (2023 to 2025), Kyverna Therapeutics, Inc.'s Net Income Loss has declined by 167.2%.
- Historical annual values: Fiscal year 2025: -$161.31 million | Fiscal year 2024: -$127.48 million | Fiscal year 2023: -$60.37 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: